PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas

PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas

The programmed death-ligands, PD-L1 and PD-L2, reside on tumor cells and can bind with programmed death-1 protein (PD-1) on T-cells, resulting in tumor immune escape. PD-1 ligands are highly expressed in some CD30+ large cell lymphomas, including classic Hodgkin lymphoma (CHL), primary mediastinal l...

Full description

Bibliographic Details
Main Authors:	Wei Xie, L. Jeffrey Medeiros, Shaoying Li, Guilin Tang, Guang Fan, Jie Xu
Format:	Article
Language:	English
Published:	MDPI AG 2022-07-01
Series:	Biomedicines
Subjects:	PD-1 PD-L1 CD30 large cell lymphoma
Online Access:	https://www.mdpi.com/2227-9059/10/7/1587

Similar Items

Prognostic Value of PD-L1, PD-1 and CD8A in Canine Diffuse Large B-Cell Lymphoma Detected by RNAscope
by: Luca Aresu, et al.
Published: (2021-06-01)

PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma
by: Raphael E. Steiner, et al.
Published: (2023-03-01)

Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma
by: Manal Mohamed Saber
Published: (2022-02-01)

Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma
by: Heli Vajavaara, et al.
Published: (2021-01-01)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
by: Hiroo Katsuya, et al.
Published: (2023-11-01)

Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases—A Possible Association with High Rheumatoid Arthritis Disease Activity
by: Erik Hellbacher, et al.
Published: (2022-03-01)

Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment
by: Jingbo Zhang, et al.
Published: (2023-12-01)

PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression
by: Federica Costa, et al.
Published: (2021-01-01)

Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment
by: Chen Chen, et al.
Published: (2021-06-01)

Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma
by: Young Wha Koh, et al.
Published: (2023-03-01)

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
by: Christie P. M. Verkleij, et al.
Published: (2020-12-01)

Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I studyResearch in context
by: Yongxian Hu, et al.
Published: (2023-06-01)

Extracellular vesicles recovered from plasma of severe dengue patients induce CD4+ T cell suppression through PD-L1/PD-1 interaction
by: Sharda Kumari, et al.
Published: (2023-12-01)

The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
by: Tianye Li, et al.
Published: (2024-03-01)

The PD-1/PD-L1 Axis in the Biology of MASLD
by: Rosaria Maria Pipitone, et al.
Published: (2024-03-01)

PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
by: Enrico Munari, et al.
Published: (2021-05-01)

PD-1/PD-L1 Checkpoints and Resveratrol: A Controversial New Way for a Therapeutic Strategy
by: Dominique Delmas, et al.
Published: (2021-09-01)

CD155 Cooperates with PD-1/PD-L1 to Promote Proliferation of Esophageal Squamous Cancer Cells via PI3K/Akt and MAPK Signaling Pathways
by: Xiyang Tang, et al.
Published: (2022-11-01)

Meta-analysis of the correlation between glioma prognosis and PD-1/PD-L1 expression
by: Chang-cheng Ren, et al.
Published: (2023-12-01)

The effect of PD-1/PD-L1 signaling axis on the interaction between CD19+B cells and CD4+T cells in peripheral blood of patients with systemic lupus erythematosus
by: Zhuobei Xie, et al.
Published: (2023-10-01)

PD-1/PD-L1 axis in organ fibrosis
by: Youliang Zhao, et al.
Published: (2023-05-01)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
by: Olga Yajuk, et al.
Published: (2021-06-01)

High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood
by: Kimberly Krueger, et al.
Published: (2022-09-01)

The prognostic significance of programmed cell death protein 1 and its ligand on lymphoma cells and tumor-immune cells in diffuse large B-cell lymphoma, not otherwise specified
by: Slak Teja Cas, et al.
Published: (2024-02-01)

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy
by: Shengzhe Jin, et al.
Published: (2024-03-01)

Membrane (CD8⁺PD-1⁺ and CD4+PD-1⁺) and soluble (sPD-1 and sPD-L1) forms of immune checkpoints in melanoma, breast cancer, and oral mucosal cancer patients: A observational study
by: Tatiana N. Zabotina, et al.
Published: (2023-12-01)

PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
by: Xiaohui Ren, et al.
Published: (2024-04-01)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
by: Sara Zalba, et al.
Published: (2020-06-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome
by: Sandra Lassalle, et al.
Published: (2020-11-01)

Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood
by: Kimberly Krueger, et al.
Published: (2022-10-01)

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
by: Hongbo Zhang, et al.
Published: (2021-06-01)

Tumor‐associated macrophages regulate the function of cytotoxic T lymphocyte through PD‐1/PD‐L1 pathway in multiple myeloma
by: Jiangbo Zhang, et al.
Published: (2022-12-01)

PD-L1/PD-1 pathway: a potential neuroimmune target for pain relief
by: Daling Deng, et al.
Published: (2024-04-01)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
by: Liudmila Spirina, et al.
Published: (2021-09-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01)

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
by: Jia-Wen Cui, et al.
Published: (2024-02-01)

Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Inﬂuenza A (H1N1)
by: A. V. Malyarchikov, et al.
Published: (2021-08-01)

Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer
by: Adrian Dumitru, et al.
Published: (2022-10-01)

Sarcoma – correlation between CD73 and PD-L1 and their relationship with prognosis
by: Abdullah Evren Yetişir, et al.
Published: (2023-03-01)